Ceralasertib联合度伐利尤单抗治疗抗PD-1治疗失败的晚期转移性黑色素瘤的II期研究
这项II期试验评估了口服ATR抑制剂ceralasertib联合度伐利尤单抗,用于抗PD-1治疗失败的转移性黑色素瘤患者。30例患者中客观缓解率为31.0%,疾病控制率为63.3%,中位缓解持续时间8.8个月,中位无进展生存期7.1个月,中位总生存期14.2个月。常见不良事件主要为血液学毒性,可通过剂量中断和减量管理。
要点
- 抗PD-1失败转移性黑色素瘤中,该联合方案客观缓解率31.0%、疾病控制率63.3%。
- 中位无进展生存期7.1个月,中位总生存期14.2个月,中位缓解持续时间8.8个月。
- 肢端、黏膜和皮肤黑色素瘤均观察到缓解,血液学毒性可管理。
核心结论
- Ceralasertib联合度伐利尤单抗在抗PD-1治疗失败的转移性黑色素瘤患者中显示出有前景的抗肿瘤活性,该人群存在未满足的临床需求。
研究设计与样本
- II期试验,评估ceralasertib联合度伐利尤单抗治疗抗PD-1治疗失败的转移性黑色素瘤患者,共30例。
主要发现
- 30例患者中客观缓解率为31.0%,疾病控制率为63.3%。
- 肢端、黏膜和皮肤黑色素瘤患者均观察到缓解。
- 中位缓解持续时间为8.8个月(范围3.8-11.7个月)。
- 中位无进展生存期为7.1个月(95%CI 3.6-10.6个月),中位总生存期为14.2个月(95%CI 9.3-19.1个月)。
- 探索性生物标志物分析提示,免疫富集微环境或DDR通路改变的肿瘤更可能对研究治疗有反应。
临床怎么用
- 对于抗PD-1治疗失败的转移性黑色素瘤患者,可考虑ceralasertib联合度伐利尤单抗作为潜在治疗选择。
- 治疗期间常见血液学不良事件,可通过剂量中断和减量进行管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Modulating the DNA damage response and repair (DDR) pathways is a promising strategy for boosting cancer immunotherapy. Ceralasertib (AZD6738) is an oral inhibitor of the serine/threonine protein kinase ataxia telangiectasia and Rad3-related protein, which is crucial for DDR. PATIENTS AND METHODS: This phase II trial evaluated ceralasertib plus durvalumab for the treatment of patients with metastatic melanoma who had failed anti-programmed cell death protein 1 therapy. RESULTS: Among the 30 patients, we observed an overall response rate of 31.0% and a disease control rate of 63.3%. Responses were evident across patients with acral, mucosal, and cutaneous melanoma. The median duration of response was 8.8 months (range, 3.8-11.7 months). The median progression-free survival was 7.1 months (95% confidence interval, 3.6-10.6 months), and the median overall survival was 14.2 months (95% confidence interval, 9.3-19.1 months). Common adverse events were largely hematologic and manageable with dose interruptions and reductions. Exploratory biomarker analysis suggested that tumors with an immune-enriched microenvironment or alterations in the DDR pathway were more likely to respond to the study treatment. CONCLUSION: We conclude that ceralasertib in combination with durvalumab has promising antitumor activity among patients with metastatic melanoma who have failed anti-programmed cell death protein 1 therapy, and constitute a population with unmet needs.
引用
- Kim R, Kwon M, An M, et al. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced/metastatic melanoma who have failed prior anti-PD-1 therapy. Ann Oncol. 2021. PMID: 34710570. doi:10.1016/j.annonc.2021.10.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。